Clinical Trials Browser

Terminated × OTHER × Carcinoma in Situ × Clear all

NCT02901548 2022-07-29

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

Phase 2 Terminated

17 enrolled 9 charts

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT00260598 2018-09-13

LIFE-Lung Bronchoscopy in Patients at Risk for Developing Lung Cancer

Phase 2 Terminated

Carcinoma in Situ, Carcinoma, Non-Small-Cell Lung, Pulmonary Disease, Chronic Obstructive

NCT03106610 2018-05-24

Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy

Phase 1 Terminated

Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT00410865 2011-12-07

Wild Type p53 Adenovirus for Oral Premalignancies

Phase 1 Terminated

Carcinoma in Situ, Mouth Neoplasms